Evidence for therapy of uveal melanomas is mostly based on single-center case series evaluating only a single therapeutic modality, often with retrospectively collected data, which may be incomplete and inaccurate. In many cases, the data cannot be compared with those of other centers because they are not collected in a uniform way. There is a need for multicenter collaboration with standardized data collection. This would enhance opportunities for multicenter randomized trials. Such studies should base their evaluations not only on local tumor control, vision and ocular conservation, but also on patient-reported outcomes. Such PROMs require sequential analyses at different time points in the patient's care pathway, taking account of all relevant factors, such as family support, concurrent and unrelated disease, and personality. Studies on metastasis-free survival should take account of genetic tumor type, using laboratory and statistical methods that have undergone external validation in several centers. Organizations such as the European Ophthalmic Oncology Group, the American Association of Ophthalmic Oncologists and Pathologists and the International Society of Ocular Oncology should strive to facilitate such studies.
Supported by That Man May See Inc.
Int Ophthalmol Clin. 2015;55(1):23-43. © 2015 Lippincott Williams & Wilkins